nach oben

International Urogynecology Journal

Erschienen in:

01.11.2008 | Review

Resiniferatoxin in the treatment of interstitial cystitis: a systematic review

verfasst von: Eleni G. Mourtzoukou, Christos Iavazzo, Matthew E. Falagas

Erschienen in: International Urogynecology Journal | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Resiniferatoxin, a treatment based on a physiopathological concept (the involvement of C fibers and transient receptor potential vanilloid 1 in the transmission of pain) is undergoing evaluation for interstitial cystitis. We evaluated the current evidence from relevant studies identified in PubMed and Scopus databases. Six studies provided contradictory results regarding the effectiveness of resiniferatoxin treatment. The largest study showed no improvement of overall symptoms following a single administration of resiniferatoxin. Three other articles that studied the effectiveness of a single dose of resiniferatoxin gave contradictory results. However, the other two studies, those that examined the effect of multiple or prolonged administration schemes, gave more encouraging results. The use of the regimen is generally well tolerated although mild adverse events such as increase of bladder pain during instillation were sometimes reported by patients and serious adverse events rarely occur. In conclusion, the effectiveness of resiniferatoxin in the treatment of interstitial cystitis remains unknown.

Appendino G, Szallasi A (1997) Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci 60:681–696PubMedCrossRef

Szallasi A, Blumberg PM (1989) Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 30:515–520PubMedCrossRef

Szallasi A, Blumberg PM (1990) Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci 47:1399–1408PubMedCrossRef

Avelino A, Cruz F (2006) TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedeberg’s Arch Pharmacol 373:287–299CrossRef

Silva C, Rio ME, Cruz F (2000) Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 38:444–452PubMedCrossRef

Silva C, Ribeiro MJ, Cruz F (2002) The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 168:575–579PubMedCrossRef

Kissin EY, Freitas CF, Kissin I (2005) The effects of intraarticular resiniferatoxin in experimental knee-joint arthritis. Anesth Analg 101:1433–1439PubMedCrossRef

Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z, Mannes AJ (2005) Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology 103:1052–1059PubMedCrossRef

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187:116–126PubMedCrossRef

10.

Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis. Eur Urol 47:393–397PubMedCrossRef

11.

Rosenberg MT, Hazzard M (2005) Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol 174:2231–2234PubMedCrossRef

12.

Kallestrup EB, Jorgensen SS, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147PubMedCrossRef

13.

Jones CA, Nyberg L (1997) Epidemiology of interstitial cystitis. Urology 49(5A Suppl):2–9PubMedCrossRef

14.

Gupta SK, Pidcock L, Parr NJ (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 96:1063–1066PubMedCrossRef

15.

Parsons CL, Stein PC, Bidair M, Lebow D (1994) Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 13:515–520PubMedCrossRef

16.

Moldwin RM, Sant GR (2002) Interstitial cystitis: a pathophysiology and treatment update. Clin Obstet Gynecol 45:259–272PubMedCrossRef

17.

Morales A, Emerson L, Nickel JC (1996) Treatment of refractory interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 7:215–220PubMedCrossRef

18.

Ruggieri MR, Chelsky MJ, Rosen SI, Shickley TJ, Hanno PM (1994) Current findings and future research avenues in the study of interstitial cystitis. Urol Clin North Am 21:163–176PubMed

19.

Nordling J, Jorgensen S, Kallestrup E (2001) Cystistat for the treatment of interstitial cystitis: a 3-year follow-up study. Urology 57(6 Suppl 1):123PubMedCrossRef

20.

Parsons CL (2004) Current strategies for managing interstitial cystitis. Expert Opin Pharmacother 5:287–293PubMedCrossRef

21.

Parsons CL, Housley T, Schmidt JD, Lebow D (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73:504–507PubMedCrossRef

22.

Parsons CL (1982) Prevention of urinary tract infection by the exogenous glycosaminoglycan sodium pentosanpolysulfate. J Urol 127:167–169PubMed

23.

Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME (2007) Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis. Eur Urol 51:1534–1541PubMedCrossRef

24.

Peng CH, Kuo HC (2007) Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol Int 78:78–81PubMedCrossRef

25.

Apostolidis A, Gonzales GE, Fowler CJ (2006) Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 50:1299–1305PubMedCrossRef

26.

Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, Perez-Marrero R, Jacoby K, Diokno AC, O’Reilly KJ, Griebling TL, Vasavada SP, Yu AS, Frumkin LR, ICOS RTX Study Group (Resiniferatoxin Treatment for Interstitial Cystitis) (2005) Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 173:1590–1594PubMedCrossRef

27.

Chen TY, Corcos J, Camel M, Ponsot Y, Tu le M (2005) Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC). Int Urogynecol J Pelvic Floor Dysfunct 16:293–297PubMedCrossRef

28.

Lazzeri M, Spinelli M, Beneforti P, Malaguti S, Giardiello G, Turini D (2004) Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study. Eur Urol 45:98–102PubMedCrossRef

29.

Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D (2000) Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 164:676–679PubMedCrossRef

30.

Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow-up. J Urol 179:1031–1034PubMedCrossRef

Titel: Resiniferatoxin in the treatment of interstitial cystitis: a systematic review
verfasst von: Eleni G. Mourtzoukou
Christos Iavazzo
Matthew E. Falagas
Publikationsdatum: 01.11.2008
Verlag: Springer-Verlag
Erschienen in: International Urogynecology Journal / Ausgabe 11/2008
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-008-0663-2

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2008

Preferences and concerns for delivery: an antepartum survey

Vaginal smooth muscle cell apoptosis is increased in women with pelvic organ prolapse

COL1A1 Sp1-binding site polymorphism as a risk factor for genital prolapse

Ethnic differences in women’s knowledge level and other barriers to care seeking and the true incidence and/or prevalence rate of female pelvic floor disorders

Surgical repair of a vesicovaginal fistula guided by a black braided silk suture line